Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro ...

Lilly Ghalichi is a lawyer-turned-beauty mogul and entrepreneur, as well as the CEO and Founder of Lilly Lashes—a brand worn ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...